@. Gardner, J. Faulkner, A. Mahalatchimy, A. Webster, and A. , Are there specific translational challenges in regenerative medicine? Lessons from other fields. Regenera7ve Medicine, pp.885-895, 2015.

@. R. Isasi, V. Rahimzadeh, and K. Charlebois, Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments, Applied & Translational Genomics, vol.11, pp.27-39, 2016.
DOI : 10.1016/j.atg.2016.11.001

@. M. Lowdell, A. Thomas, . A. @bullet, A. Mahalatchimy, and . Faulkner, The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products First published online 17 doi: 10.1111/bjh.14384 ? A. Mahalatchimy, Reimbursement of cell-based regenerative therapy in the UK and France The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics, British Journal of Haematology Medical Law Review Regenerative Medicine, vol.176, issue.12 6, pp.9-15, 2016.

@. A. Webster, Regenerative medicine and responsible research and innovation: proposals for a responsible acceleration to the clinic, Regenerative Medicine, vol.22, issue.1, pp.853-864, 2017.
DOI : 10.1080/23299460.2016.1259929